Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

5/28/24 8:03:03 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $BNGO alert in real time by email

Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024.

Get the next $BNGO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BNGO

Date	Price Target	Rating	Analyst
11/15/2024		Buy → Neutral	Ladenburg Thalmann
9/10/2024		Buy → Neutral	BTIG Research
1/5/2023	$4.00	Sector Outperform	Scotiabank
12/12/2022	$3.50	Buy	BTIG Research
7/18/2022	$12.00	Outperform	Oppenheimer

More analyst ratings

$BNGO
Market Insights

Live Market Insights

Bionano Announces Publication Of First Multi-Site Study To Analyze The Utility Of OGM In Multiple Myeloma
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs).Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is critical for patient risk stratification, predication of response to therapy options, and understanding of pathogenesis, many genome analysis methodologies, including fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA), are li
7/23/24 8:15:25 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano Enters Agreements With Institutional Investors For For $30M Registered Direct Offering; Purchase And Sale Of 17,513,136 Shares At $0.571/Share
7/5/24 8:02:08 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano Presents OGM Utility Across Stem Cell Therapy Applications At The ISSCR Annual Meeting
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applicationsTwo scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conferenceSAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2024 with a broad range of content cove
7/2/24 8:07:01 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials

$BNGO
Press Releases

Fastest customizable press release news feed in the world

Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. Q3 2024 revenue represents a 35% decrease from Q3 2023Total installed base of 368 optical genome mapping (OGM) systems as of Q3 2024, which represents a 22% increase over Q3 2023Sold 7,835 nanochannel array flowcells in Q3 2024, which represents a 27% increase from the number of flowcells sold in Q3 2023Conference call today, November 13, 2024 at 4:30 PM ET SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results
11/13/24 4:01:00 PM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
11/7/24 4:01:00 PM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the "Warrants") at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the
10/31/24 4:30:00 PM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials

Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
11/7/24 4:01:00 PM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 7th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/jojadok2/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
7/31/24 8:00:00 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/mmc/p/5z343pph/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor re
5/1/24 8:00:00 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials

LeddarTech Appoints Chris Stewart as Chief Financial Officer
QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial
11/15/23 12:07:00 AM ET
$BNGO
$PRSR
$TSLA
Biotechnology: Laboratory Analytical Instruments
Industrials
Blank Checks
Finance
Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe
8/14/23 8:00:00 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials
Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l
11/10/22 8:00:00 AM ET
$BNGO
Biotechnology: Laboratory Analytical Instruments
Industrials

Bionano Receives $18M In Private Placement Of Senior Secured Notes In Debt Restructuring That Improves Balance Sheet

Chat with this insight

Recent Analyst Ratings for $BNGO

$BNGO SEC Filings

SEC Form 10-Q filed by Bionano Genomics Inc.

Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Bionano Genomics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$BNGO Market Insights

Live Market Insights

Bionano Announces Publication Of First Multi-Site Study To Analyze The Utility Of OGM In Multiple Myeloma

Bionano Enters Agreements With Institutional Investors For For $30M Registered Direct Offering; Purchase And Sale Of 17,513,136 Shares At $0.571/Share

Bionano Presents OGM Utility Across Stem Cell Therapy Applications At The ISSCR Annual Meeting

$BNGO Press Releases

Fastest customizable press release news feed in the world

Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress

Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

$BNGO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

$BNGO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

New insider Adamchak Mark claimed ownership of 16,471 shares (SEC Form 3)

Chief Operating Officer Oldakowski Mark covered exercise/tax liability with 3,568 shares, decreasing direct ownership by 6% to 61,283 units (SEC Form 4)

$BNGO Financials

Live finance-specific insights

$BNGO Leadership Updates

Live Leadership Updates

$BNGO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

Bionano to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 7, 2024

Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024

LeddarTech Appoints Chris Stewart as Chief Financial Officer

Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

Bionano Genomics downgraded by Ladenburg Thalmann

Bionano Genomics downgraded by BTIG Research

Scotiabank initiated coverage on Bionano Genomics with a new price target

Recent Analyst Ratings for
$BNGO

$BNGO
SEC Filings

$BNGO
Market Insights

$BNGO
Press Releases

$BNGO
Large Ownership Changes

$BNGO
Insider Trading

$BNGO
Financials

$BNGO
Leadership Updates

$BNGO
Analyst Ratings